Summit Q2 2026: Ivonescimab OS Data Strengthens, Cash at $691M, ATM Raised $299M
SMMT sits 16% above its 52-week low of $12.55.
Summary
Summit reported Q2 2026 results with $691M in cash, raised $299M via its ATM, and presented updated HARMONi overall survival data showing consistent benefit across regions — strengthening the case for ivonescimab's November 2026 FDA decision.
Key Events · Earnings and Guidance · SMMT
-
Updated HARMONi OS Data Consistent Across Regions
A new analysis reveals a hazard ratio of 0.76 for overall survival in the full ITT population, with the same 0.76 HR in both Asian and Western subgroups — reinforcing geographic translatability ahead of the November 14, 2026 PDUFA date.
-
ATM Facility Raised $299M in Recent Months
Through its ATM, Summit raised $230.8 million in gross proceeds during Q2 2026 and an additional $68.4 million subsequent to quarter end, contributing to a $690.7 million cash and investments balance as of June 30, 2026.
-
Non-GAAP Operating Expenses Surge 69% YoY
Non-GAAP operating expenses reached $151.8 million in Q2 2026, up from $89.6 million a year ago, driven by expansion of ivonescimab clinical trials and infrastructure build-out ahead of potential commercialization.
-
HARMONi-3 PFS Data Expected 2H 2026; Interim OS Planned
Enrollment is complete in both squamous and non-squamous cohorts of the global HARMONi-3 study; squamous PFS events are expected in the second half of 2026 with a concurrent interim OS analysis, and non-squamous PFS in the first half of 2027.
Analysis · SMMT · Life Sciences
Summit's Q2 update reinforces the clinical case for ivonescimab ahead of the November 2026 PDUFA date. Updated HARMONi data shows a consistent 0.76 hazard ratio for overall survival in both Asian and Western patients, addressing a key regulatory question about geographic translatability. The company burned through $263M in operating cash in the first half of 2026 but offset it with $235M from financing — primarily $231M from the ATM in Q2 alone, with another $68M raised after the quarter. Non-GAAP operating expenses jumped 69% year-over-year to $152M as the global Phase III program expands. With $691M in cash and no debt, Summit has runway through multiple upcoming catalysts: HARMONi-3 squamous PFS data in 2H 2026, the November 14 PDUFA, and interim OS analyses in 1H 2027. The ATM overhang is real — the company has been actively selling into the market — but the cash position removes near-term dilution risk and funds the build-out toward a potential commercial launch.
At the time of this filing, SMMT was trading at $14.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.6B. The 52-week trading range was $12.55 to $30.98. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.